Can Light Therapy Help with Dementia?
The evidence is promising. This systematic review of studies from 1967 to 2020 found that photobiomodulation using red and near-infrared light showed positive effects on brain function in both pre-clinical models and early clinical studies of dementia, including Alzheimer’s disease.
Red light therapy, also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), uses specific wavelengths of red and near-infrared light to promote healing and reduce inflammation.
Dementia, including Alzheimer’s disease, remains one of the greatest challenges in medicine. Current medications provide limited benefit, and there is no cure. Photobiomodulation (PBM), which uses red or near-infrared light delivered through the skull and sometimes intranasally, has emerged as a potential treatment approach. This systematic review compiled and analyzed all available research on PBM for dementia to determine where the evidence stands.
What the Research Shows
The review followed PRISMA guidelines and searched literature from 1967 to 2020 using keywords related to both photobiomodulation and dementia. The researchers carefully documented the light parameters used in each study, including wavelength, output power, energy density, treatment duration, total dose, continuous versus pulsed mode, and the number of treatment sessions. Both pre-clinical and clinical studies showed positive outcomes. The clinical studies reported improvements in cognitive function, behavior, and quality of life in patients with mild to moderate dementia. The parameters that appeared most effective involved near-infrared wavelengths around 800 to 1064 nm, delivered transcranially, sometimes combined with intranasal application.
Dr. Kumar’s Take
This is one of those areas where I feel a real sense of urgency. We are failing patients with Alzheimer’s disease. The medications we have are marginally effective at best, and many come with significant side effects. PBM offers something fundamentally different. Instead of introducing a chemical into the brain, we are providing energy in the form of light that the brain’s own mitochondria can use. The studies in this review show improvements in cognitive function, and some clinicians report dramatic changes in their patients’ ability to perform daily tasks. Starting early matters tremendously. The sooner PBM is introduced in the course of cognitive decline, the more benefit it appears to provide.
How Light Reaches the Brain
A common question is whether light can actually penetrate the skull. The answer is yes, but only about 2 to 3 percent of the applied light reaches the brain’s outer layers. This is why high-power devices are preferred for transcranial applications, since starting with more light means more reaches the target. Near-infrared wavelengths, particularly around 800 nm and 1064 nm, penetrate bone and tissue more effectively than visible red light. Some protocols also use intranasal delivery, where light is applied through the nasal cavity to reach areas of the brain that are closer to the surface through that route.
Practical Takeaways
- Red light therapy shows promise for improving cognitive function in people with dementia, especially when started early.
- Near-infrared wavelengths (800-1064 nm) are preferred for transcranial applications due to better skull penetration.
- PBM is not a cure for dementia, but may slow decline and improve quality of life as a supportive therapy.
- Home-use transcranial PBM devices are becoming available, though clinical devices offer higher power.
FAQs
Can photobiomodulation prevent Alzheimer’s disease?
Prevention studies have not yet been conducted in humans. However, the biological mechanisms of PBM, such as reducing neuroinflammation, improving blood flow, and enhancing mitochondrial function, are all factors that contribute to brain health. It is plausible that regular PBM use could support brain health over time, but this has not been proven in clinical trials.
How often should someone with dementia use transcranial PBM?
The clinical studies in this review varied in their protocols, but most involved treatments several times per week. Some home-use devices are designed for daily sessions of about 10 to 20 minutes. The key is consistency, as the benefits of PBM build over time through repeated treatments.
Is transcranial PBM safe for elderly patients?
Yes. The review found no serious adverse effects from transcranial PBM. The light does not heat the brain tissue to any meaningful degree, and it does not involve radiation. PBM is well tolerated by elderly patients, and the treatment itself is painless and noninvasive.
Bottom Line
This systematic review supports the potential of Red light therapy as a treatment for dementia, including Alzheimer’s disease. While more large-scale clinical trials are needed, the existing evidence shows improvements in cognitive function with a therapy that is safe, noninvasive, and well tolerated. For families facing a dementia diagnosis, PBM represents a promising supportive treatment worth exploring.
